We are live on ! Find out more
BC

Boxer Capital Portfolio holdings

AUM $2.04B
1-Year Est. Return 108.39%
This Fund
S&P 500
This Quarter Est. Return
-0.45%
1 Year Est. Return
+108.39%
3 Year Est. Return
+261.8%
5 Year Est. Return
+1,135.09%
10 Year Est. Return
–
AUM
$2.57B
AUM Growth
-$289M
Cap. Flow
-$70.1M
Cap. Flow %
-2.72%
Top 10 Hldgs %
55.83%
Holding
95
New
7
Increased
6
Reduced
12
Closed
24

Top Buys

Rank Stock Value
1
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$265M
2
RLAY icon
Relay Therapeutics
RLAY
+$43.5M
3
FATE icon
Fate Therapeutics
FATE
+$28.3M
4
RARE icon
Ultragenyx Pharmaceutical
RARE
+$16.3M
5
PMVP icon
PMV Pharmaceuticals
PMVP
+$13.8M

Top Sells

Rank Stock Value
1
ONC
BeOne Medicines Ltd
ONC
+$89.2M
2
ARGX icon
argenx
ARGX
+$51.6M
3
CNTB
Connect Biopharma Holdings
CNTB
+$50.4M
4
SNDX icon
Syndax Pharmaceuticals
SNDX
+$43.7M
5
FULC icon
Fulcrum Therapeutics
FULC
+$35.3M

Sector Composition

Rank Sector Weight
1 Healthcare 87.19%
2 Financials 0.83%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MRTX
1
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$293M 11.39%
2,000,000
– –
XBI icon
2
State Street SPDR S&P Biotech ETF
XBI
$9.95B
$246M 9.57%
+2,200,000
New +$265M
ITOS
3
DELISTED
iTeos Therapeutics
ITOS
$202M 7.86%
4,345,016
– –
ONC
4
BeOne Medicines Ltd
ONC
$32.8B
$135M 5.26%
500,000
-264,188
-35% -$89.2M
SWTX
5
DELISTED
SpringWorks Therapeutics
SWTX
$129M 5%
2,075,905
– –
CYTK icon
6
Cytokinetics
CYTK
$10.5B
$95.7M 3.72%
2,100,000
– –
TYRA icon
7
Tyra Biosciences
TYRA
$1.9B
$90.7M 3.52%
6,448,359
+125,000
+2% +$2.48M
RVMD icon
8
Revolution Medicines
RVMD
$39.9B
$87.7M 3.41%
3,484,264
– –
RLAY icon
9
Relay Therapeutics
RLAY
$4.1B
$82M 3.18%
2,669,132
+1,375,000
+106% +$43.5M
TNGX icon
10
Tango Therapeutics
TNGX
$4.43B
$75.2M 2.92%
6,871,642
– –
PMVP icon
11
PMV Pharmaceuticals
PMVP
$59.2M
$65.6M 2.55%
2,838,236
+570,000
+25% +$13.8M
XNTK icon
12
CALL
State Street SPDR NYSE Technology ETF
XNTK
$2.06B
$61.6M 2.39%
+550,000
New +$91.3M
MRUS
13
DELISTED
Merus
MRUS
$60.4M 2.35%
1,900,000
– –
RCUS icon
14
Arcus Biosciences
RCUS
$3.55B
$58M 2.25%
1,432,200
-652,683
-31% -$25.3M
BPMC
15
DELISTED
Blueprint Medicines
BPMC
$54.3M 2.11%
507,374
+82,374
+19% +$8.62M
IDYA icon
16
IDEAYA Biosciences
IDYA
$3.42B
$52.1M 2.02%
2,202,812
– –
SAGE
17
DELISTED
Sage Therapeutics
SAGE
$46.5M 1.81%
1,094,000
– –
ANAB icon
18
AnaptysBio
ANAB
$1.58B
$45.2M 1.75%
1,300,000
– –
NUVB icon
19
Nuvation Bio
NUVB
$2.2B
$36.9M 1.43%
4,341,009
– –
NRIX icon
20
Nurix Therapeutics
NRIX
$2.41B
$35.5M 1.38%
1,224,892
– –
KNTE
21
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
$32.7M 1.27%
1,847,559
– –
RCKT icon
22
Rocket Pharmaceuticals
RCKT
$340M
$32M 1.24%
1,466,051
– –
FATE icon
23
Fate Therapeutics
FATE
$286M
$29.3M 1.14%
+500,000
New +$28.3M
GOSS icon
24
Gossamer Bio
GOSS
$82.9M
$27.8M 1.08%
2,462,358
– –
FOLD
25
DELISTED
Amicus Therapeutics
FOLD
$26.9M 1.04%
2,325,000
– –
1
2 3 4

Similar funds

FTDI
First Trust Direct Indexing Boston, Massachusetts $1.87B AUM 43.63% 1-Year Est. Return
CIM
Contrarius Investment Management St. Helier, Jersey $1.76B AUM 35.87% 1-Year Est. Return
PRO
Pensioenfonds Rail & OV Utrecht, Netherlands $1.44B AUM 23.73% 1-Year Est. Return
GFS
GYL Financial Synergies West Hartford, Connecticut $1.33B AUM 34.46% 1-Year Est. Return
ECM
Ensemble Capital Management San Francisco, California $1.18B AUM 41.81% 1-Year Est. Return
CIP
Chartwell Investment Partners Berywn, Pennsylvania $2.91B AUM 40.48% 1-Year Est. Return
SEC
Seven Eight Capital New York $1.11B AUM 29.48% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Boxer Capital's Q4 2021 Portfolio in Review

As of Q4 2021, Boxer Capital held 95 positions worth $2.57B, down 10% from $2.86B the previous quarter. Its ten largest holdings account for 56% of the portfolio.

Boxer Capital's Q4 2021 filing shows 7 new, 6 increased, 12 reduced and 24 closed positions. Its largest new stake was State Street SPDR S&P Biotech ETF: 2,200,000 shares worth $246M. The largest sale was BeOne Medicines Ltd, an estimated $89.2M.

By sector, the portfolio is most concentrated in Healthcare at 87% of assets, down from 98% a quarter earlier, followed by Financials.

  • Boxer Capital's largest Q4 2021 buy was State Street SPDR S&P Biotech ETF: 2,200,000 shares worth $246M.
  • Boxer Capital added most to Relay Therapeutics in Q4 2021, an estimated $43.5M increase.
  • Boxer Capital's biggest Q4 2021 reduction was BeOne Medicines Ltd, cutting an estimated $89.2M.
  • Boxer Capital fully exited argenx in Q4 2021, selling an estimated $51.6M.
  • Boxer Capital's ten largest holdings make up 56% of its $2.57B portfolio in Q4 2021.
  • Boxer Capital opened 7 new positions and closed 24 in Q4 2021.
  • Boxer Capital's portfolio value fell 10% quarter-over-quarter to $2.57B.

Based on Boxer Capital's 13F filing for Q4 2021, filed 14 Feb 2022.